NICE has published draft guidelines rejecting Sanofi Genzyme’s Caprelsa for treating medullary thyroid cancer (MTC) that cannot be operated on or has spread around the body.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.